Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 19/20 | 0.85 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524141 | 0.96 | MCHR1 (0.91) | MCHR1ADRA2ANPY5R | |
| SCHEMBL13793932 | 0.92 | MCHR1 (1.00) | MCHR1ADRA2ANPY5R | |
| SCHEMBL13794149 | 0.92 | MCHR1 (1.00) | MCHR1ADRA2ANPY5R | |
| Trifluoroacetic Acid SCHEMBL3941752 | 0.91 | MCHR1 (0.82) | MCHR1ADRA2ANPY5R | |
| Hydrochloric Acid SCHEMBL3937515 | 0.91 | MCHR1 (0.98) | MCHR1ADRA2ANPY5R | |
| Hydrochloric Acid SCHEMBL3938597 | 0.91 | MCHR1 (0.98) | MCHR1ADRA2ANPY5R | |
| Hydrochloric Acid SCHEMBL3937512 | 0.91 | MCHR1 (0.98) | MCHR1ADRA2ANPY5R | |
| SCHEMBL13796636 | 0.87 | MCHR1 (0.87) | MCHR1ADRA2ANPY5R | |
| SCHEMBL3938796 | 0.86 | MCHR1 (1.00) | MCHR1ADRA2ANPY5R | |
| SCHEMBL3938794 | 0.86 | MCHR1 (1.00) | MCHR1ADRA2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MCHR1 1/4885ADRA2A 103/4885NPY5R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.